• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血友病:凝血因子供应与新型疗法:世界血友病联盟的目标与成就

Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements.

作者信息

Skinner Mark W

机构信息

World Federation of Hemophilia, Washington, DC, USA.

出版信息

Br J Haematol. 2011 Sep;154(6):704-14. doi: 10.1111/j.1365-2141.2011.08765.x. Epub 2011 Jun 28.

DOI:10.1111/j.1365-2141.2011.08765.x
PMID:21707577
Abstract

For nearly 50 years, the goal of the World Federation of Hemophilia (WFH) has been to achieve 'Treatment for All' patients with inherited bleeding disorders, regardless of where they live. With proper diagnosis, management and care, people with bleeding disorders can live perfectly healthy lives. Without treatment, the reality is that many will die young or, if they survive, suffer joint damage that leaves them with permanent disabilities. Only about 25% of the estimated 400 000 people with haemophilia worldwide receive adequate treatment. The percentage is far lower for those with von Willebrand Disease (VWD) and the rarer bleeding disorders. The achievements of the WFH to close the gap in care for people with bleeding disorders are measureable over time by using three key indicators; the difference in the estimated and actual number of people known with bleeding disorders, the amount of treatment products needed versus that available, and the number of people born with bleeding disorders and the number who reach adulthood. There are five essential elements to achieve a sustainable national care programme: ensuring accurate laboratory diagnosis, achieving government support, improving the care delivery system, increasing the availability of treatment products, and building a strong national patient organization.

摘要

近50年来,世界血友病联盟(WFH)的目标一直是让所有遗传性出血性疾病患者都能得到治疗,无论他们身处何地。通过适当的诊断、管理和护理,出血性疾病患者能够过上完全健康的生活。而如果不进行治疗,现实情况是许多患者会英年早逝,或者即便存活下来,也会遭受关节损伤,导致终身残疾。全球约40万血友病患者中,只有约25%得到了充分治疗。对于血管性血友病(VWD)患者和更罕见的出血性疾病患者而言,这一比例要低得多。通过使用三个关键指标,可以衡量世界血友病联盟在缩小出血性疾病患者护理差距方面随时间推移所取得的成就;已知出血性疾病患者的估计人数与实际人数之差、所需治疗产品数量与可用数量之比,以及患有出血性疾病的新生儿人数和成年人数。实现可持续的国家护理计划有五个基本要素:确保准确的实验室诊断、获得政府支持、改善护理提供系统、增加治疗产品的可及性,以及建立强大的国家患者组织。

相似文献

1
Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements.血友病:凝血因子供应与新型疗法:世界血友病联盟的目标与成就
Br J Haematol. 2011 Sep;154(6):704-14. doi: 10.1111/j.1365-2141.2011.08765.x. Epub 2011 Jun 28.
2
Treatment for all: a vision for the future.全民治疗:未来愿景。
Haemophilia. 2006 Jul;12 Suppl 3:169-73. doi: 10.1111/j.1365-2516.2006.01280.x.
3
WFH--the cornerstone of global development: 45 years of progress.居家办公——全球发展的基石:45年的进步
Haemophilia. 2008 Jul;14 Suppl 3:1-9. doi: 10.1111/j.1365-2516.2008.01707.x.
4
The World Federation of Hemophilia Annual Global Survey 1999-2018.《世界血友病联盟 1999-2018 年全球年度调查》。
Haemophilia. 2020 Jul;26(4):591-600. doi: 10.1111/hae.14012. Epub 2020 Jun 4.
5
WFH: closing the global gap--achieving optimal care.WFH:弥合全球差距——实现最佳护理。
Haemophilia. 2012 Jul;18 Suppl 4:1-12. doi: 10.1111/j.1365-2516.2012.02822.x.
6
Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities.中国的血友病护理:世界血友病联盟治疗中心结对活动十年成果
Haemophilia. 2008 Sep;14(5):879-88. doi: 10.1111/j.1365-2516.2008.01821.x. Epub 2008 Jul 15.
7
Haemophilia care in Europe: a survey of 19 countries.欧洲血友病护理:19 个国家的调查。
Haemophilia. 2011 Jan;17(1):35-40. doi: 10.1111/j.1365-2516.2010.02362.x. Epub 2010 Aug 16.
8
Enhancing haemophilia care through registries.通过登记处加强血友病护理。
Haemophilia. 2014 May;20 Suppl 4:121-9. doi: 10.1111/hae.12406.
9
National survey of patients with hemophilia and other congenital bleeding disorders in Thailand.泰国血友病及其他先天性出血性疾病患者的全国性调查。
Southeast Asian J Trop Med Public Health. 2004 Jun;35(2):445-9.
10
World Federation of Haemophilia programs in developing countries.世界血友病联盟在发展中国家的项目。
Semin Thromb Hemost. 2005 Nov;31(5):555-60. doi: 10.1055/s-2005-922227.

引用本文的文献

1
A Global Cross-Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A.一项关于A型血友病低剂量FVIII SHL预防的全球横断面数据库研究。
Haemophilia. 2025 Jul;31(4):646-656. doi: 10.1111/hae.70061. Epub 2025 May 10.
2
Biomarkers Involved in the Pathogenesis of Hemophilic Arthropathy.参与血友病性关节病发病机制的生物标志物。
Int J Mol Sci. 2024 Sep 13;25(18):9897. doi: 10.3390/ijms25189897.
3
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.活化因子X靶向储存在血小板中作为治疗甲型和乙型血友病的有效基因治疗策略。
Clin Transl Med. 2021 Mar;11(3):e375. doi: 10.1002/ctm2.375.
4
Comparative Analysis of the Occurrence and Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Hemophilic Arthropathy and Osteoarthritis.比较分析 CX3CL1(趋化因子)及其受体 CX3CR1 在血友病性关节病和骨关节炎中的发生和作用。
J Immunol Res. 2020 Aug 20;2020:2932696. doi: 10.1155/2020/2932696. eCollection 2020.
5
Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy.公平获得基因治疗:对美国基因与细胞治疗学会的行动呼吁。
Mol Ther. 2018 Dec 5;26(12):2715-2716. doi: 10.1016/j.ymthe.2018.11.002. Epub 2018 Nov 16.
6
Gene therapy in hemophilia A: a cost-effectiveness analysis.血友病 A 的基因治疗:成本效益分析。
Blood Adv. 2018 Jul 24;2(14):1792-1798. doi: 10.1182/bloodadvances.2018021345.
7
Congenital Factor Deficiencies in Children: A Report of a Single-Center Experience.儿童先天性因子缺乏症:单中心经验报告
Clin Appl Thromb Hemost. 2018 Sep;24(6):901-907. doi: 10.1177/1076029617731596. Epub 2017 Oct 19.
8
Successful esophagectomy in a patient with combined esophageal cancer and hemophilia B.一名患有食管癌合并乙型血友病患者成功接受了食管切除术。
World J Gastroenterol. 2014 Sep 21;20(35):12701-3. doi: 10.3748/wjg.v20.i35.12701.
9
Present and future challenges in the treatment of haemophilia: the patient's perspective.血友病治疗中的当前与未来挑战:患者视角
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s82-5. doi: 10.2450/2013.013s.
10
The demand for factor VIII and for factor IX and the toll fractionation product surplus management.对凝血因子 VIII、凝血因子 IX 的需求以及凝血因子浓缩物产品过剩管理。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s64-76. doi: 10.2450/2013.011s.